Simulating economic factors in adjuvant breast cancer treatment

When conducting an experimental study in healthcare systems, two problems are faced, those of uncertainty and complexity. Uncertainty is related to identifying variables for data collection (particularly if there are time and cost constraints on the modelling exercise). Complexity is related to the existence of many interacting variables (including treatment paths for patients, patient illnesses, side effects of treatments, etc.), each of a stochastic nature. This paper reports the usefulness of discrete event simulation modelling in exploring these issues. It focuses on the use of this form of simulation in supporting decision making in a randomised clinical trial (RCT). The objective of using simulation modelling is to help health economists identify the key factors active in the RCT through the development of a model of the healthcare related processes being studied by the RCT. This approach provides an opportunity to allow users to understand the role of these factors in the RCT. This research is carried out in the context of the Adjuvant Breast Cancer RCT.

[1]  Michael Pidd,et al.  Tools for Thinking—Modelling in Management Science , 1997 .

[2]  G. Hortobagyi,et al.  Factors predicting long‐term survival for metastatic breast cancer patients treated with high‐dose chemotherapy and bone marrow support , 1994, Cancer.

[3]  D. Whynes,et al.  The Costs of Treating Breast Cancer in the United Kingdom: Implications for Screening , 1998, International Journal of Technology Assessment in Health Care.

[4]  R. Gelman,et al.  Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Michael Pidd,et al.  Provider and customer expectations of successful simulation projects , 1998, J. Oper. Res. Soc..

[6]  D R Nerenz,et al.  Side effects and emotional distress during cancer chemotherapy , 1989, Cancer.

[7]  Vlatka Hlupic,et al.  Successful Simulation: A Practical Approach to Simulation Projects , 1995 .

[8]  S. Closs,et al.  Side effects expected and experienced by women receiving chemotherapy for breast cancer. , 1991, BMJ.

[9]  M. E. Harrison,et al.  Impact of side-effects associated with endocrine treatments for advanced breast cancer: clinicians' and patients' perceptions , 1996 .

[10]  L. Rutqvist,et al.  Late effects of adjuvant chemotherapy and postoperative radiotherapy on quality of life among breast cancer patients. , 1991, European journal of cancer.

[11]  B E Hillner,et al.  Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. , 1991, The New England journal of medicine.

[12]  C Kamby,et al.  Stage and pattern of metastases in patients with breast cancer. , 1987, European journal of cancer & clinical oncology.

[13]  S. Hurley,et al.  The cost of breast cancer recurrences. , 1992, British Journal of Cancer.

[14]  N Urban,et al.  Estimating the Treatment Costs of Breast and Lung Cancer , 1991, Medical care.

[15]  B. Hillner,et al.  The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Michael Pidd,et al.  Computer Simulation in Management Science (3rd Edition) , 1998 .

[17]  G Marini,et al.  Effect of systemic adjuvant treatment on first sites of breast cancer relapse , 1994, The Lancet.

[18]  L. Norton,et al.  Metastatic breast cancer. Length and quality of life. , 1991, The New England journal of medicine.

[19]  C. V. D. van de Velde,et al.  Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Lequaglie,et al.  Correlation between first disease-free interval from mastectomy to second disease-free interval from chest wall resection. , 1992, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  C Kamby,et al.  The pattern of metastases in human breast cancer. Influence of systemic adjuvant therapy and impact on survival. , 1988, Acta oncologica.

[22]  Earlybreastcancertrialistscol,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[23]  R. Gelber,et al.  Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  B. F. Cole,et al.  Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival , 1996, The Lancet.

[25]  Stewart Robinson,et al.  Simulation Modelling , 2001 .